Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390 is registered in ClinicalTrials.gov with Anokion SA as lead sponsor.

NCT NCT04602390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Lead sponsor
Anokion SA
Phase
Phase 1
Overall status
Completed
Start date
November 6, 2020
Completion date
April 23, 2024
Enrollment
34 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms), relapsing remitting multiple sclerosis